Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2016.074 | A proof-of-concept phase II clinical trial on the use everolimus in TSC2-hull/low hepatocellular carcinoma |
Dr. CHAN Stephen L. 陳林 |
| 2015.090 | Development of clinical model to predict the capecitabine-related toxicity in the Chinese population of colorectal cancer |
Dr. CHAN Stephen L. 陳林 |
| 2015.072 | A Phase 3, Randomized, Double-blind,Placebo-controlled Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase | Dr. CHAN Stephen Lam |
| 2014.526 | A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to gemcitabine in combination with placebo, followed as second line treatment by masitinib in combination with Folfiri 3 versus placebo in combination with Folfiri 3 in the treatment of patients with non resectable locally advanced or metastatic pancreatic cancer | Prof. CHAN Stephen Lam |
| 2016.393 | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2016.730 | A study on thromboembolism in pancreatic cancer patients |
Dr. CHAN Stephen Lam 陳林 |
| 2017.049 | A phase Ib study of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2017.653 | A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2016.172 | A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2017.661 | PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2014.535 | A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression | Prof. CHAN Stephen Lam |
| 2015.581 | A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2014.404 | A Randomized Phase 2 Study of LY2157299 versus LY2157299 – Sorafenib Combination versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2016.016 | A phase III, Open-label, Randomized Study of the Combination Therapy with NC-6004 and Gemcitabine versus Gemcitabine Alone in Patients with Locally Advanced or Metastatic Pancreatic Cancer |
Dr. CHAN Stephen Lam 陳林 |
| 2015.361 | Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib |
Dr. CHAN Stephen Lam 陳林 |
| 2017.465 | A clinical trial of pembrolizumab in patients with hepatitis B virus-related hepatocellular carcinoma, with parallel study on baseline and serial change in the immune environment |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2016.262 | A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2020.568 | FOENIX-CCA3: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements |
Dr. CHAN Stephen Lam 陳林 |
| 2019.096 | A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.636 | Targeting and monitoring MDSCs to improve outcomes of radiofrequency ablation in hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.416 | A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) | Dr. CHAN Stephen Lam |
| 2019.387 | A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in Combination with Brivanib Alaninate (ZL-2301) in Patients with Advanced Liver Cancer | Dr. CHAN Stephen Lam |
| 2019.431 | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.454 | A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy |
Dr. CHAN Stephen Lam 陳林 |
| 2019.259 | Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.458 | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2019.474 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION |
Prof. CHAN Stephen Lam 陳林 醫生 |
| 2019.219 | Study on the clinical role of the Albumin-Bilirubin-index (ALBI) in patients treated with lenvatinib or atezolizumab/bevacizumab for hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.555 | A Phase Ia/Ib, Open-Label, Dose-Escalation and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors |
Dr. CHAN Stephen Lam 陳林 |
| 2019.651 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2) |
Dr. CHAN Stephen Lam 陳林 |
| 2019.694 | A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to checkpoint inhibitors |
Dr. CHAN Stephen Lam 陳林 |
| 2020.625 | A PHASE II, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIARY TRACT CANCER |
Dr. CHAN Stephen Lam 陳林 醫生 |
| 2024.368 | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER) | Prof. CHAN Stephen Lam |
| 2024.098 | Establishment of a Hepatocellular Carcinoma Database | Prof. CHAN Stephen Lam |
| 2024.710 | DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer | Prof. CHAN Stephen Lam |
| 2025.149 | A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1) | Prof. CHAN Stephen Lam |
| 2025.306 | A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2024.379 | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements | Prof. CHAN Stephen Lam |
| 2024.253 | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol | Prof. CHAN Stephen Lam |
| 2025.184 | A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01) | Prof. CHAN Stephen Lam |
| 2024.724 | An Open-Label Phase 1/2 Study of WGI-0301 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma as Second Line Therapy |
Prof. CHAN Stephen Lam 陳林 |
| 2024.646 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination with Atezolizumab plus Bevacizumab Compared with Placebo plus Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated with Systemic Therapy | Prof. CHAN Stephen Lam |
| 2024.239 | A PHASE I STUDY OF ERY974 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA | Prof. CHAN Stephen Lam |
| 2021.605 | ORGAN-SPECIFIC RESPONSES TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A MULTINATIONAL MULTICENTER STUDY |
Prof. CHAN Stephen Lam 陳林教授 |
| 2021.017 | A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林 |
| 2022.216 | A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106) |
Prof. CHAN Stephen Lam 陳林 |
| 2023.567 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) | Prof. CHAN Stephen Lam |
| 2023.376 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 2: Biliary Tract Cancer (BTC) | Prof. CHAN Stephen Lam |
| 2022.174 | AN OPEN LABEL, RANDOMISED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MTL-CEBPA ADMINISTERED IN COMBINATION WITH SORAFENIB OR SORAFENIB ALONE, IN TKI NAÏVE PARTICIPANTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) AND HEPATITIS B OR HEPATITIS C VIRUS (OUTREACH2) |
Prof. CHAN Stephen Lam 陳林 |
| 2021.642 | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012) |
Prof. CHAN Stephen Lam 陳林教授 |
Page 67 of 265.